Vancouver Television · International

Missouri judge approves $7.25-billion settlement with Bayer over Roundup-linked non-Hodgkin lymphoma claims

Missouri judge approves $7.25-billion settlement with Bayer over Roundup-linked non-Hodgkin lymphoma claims

A Missouri judge approved a settlement under which Bayer will pay up to $7.25 billion over two decades to resolve Roundup-related cancer claims.

The Story

A Missouri judge has approved a settlement in which Bayer will pay up to $7.25 billion over the next two decades to resolve thousands of claims from U.S. cancer patients who allege the company should have warned that its Roundup weedkiller could cause non-Hodgkin lymphoma.

The nationwide settlement applies to people who are already ill and to those who are diagnosed with non-Hodgkin lymphoma in future years. Approved payouts for participants would average between $10,000 and $165,000, depending on how they used Roundup, their age when diagnosed, and the severity of their illness.

The settlement, approved Friday by St. Louis Circuit Judge Timothy Boyer, includes $600 million for attorneys’ fees. In his written judgment, Boyer said the average individual payouts are “fair and adequate” and that the total dollar amount is “among the largest in the history of mass tort personal-injury class action settlements.”

The judge said there was a risk Bayer would have sought bankruptcy protection if the settlement had been rejected, and the decision could be appealed. Bayer CEO Bill Anderson said the court-approved settlement is “a decisive milestone in the company’s strategy to mitigate the risks of both pending and future Roundup litigation.”

The agreement requires Bayer to make annual payments into a special fund for up to 21 years, totaling as much as $7.25 billion. The evidence indicates that the average amount for some workers exposed for long periods could reach $165,000 if diagnosed with an aggressive form of the illness while younger than age 60, while people diagnosed at age 78 or older would receive an average of $10,000.

The settlement follows major legal developments affecting Roundup litigation. While the settlement was pending, the U.S. Supreme Court ruled in June that Bayer cannot be sued in state courts on failure-to-warn claims because federal regulations do not require a cancer warning label and states are forbidden from imposing additional labeling requirements.

Bayer, which denies that Roundup causes cancer, has previously changed the formula for its Roundup product sold to residential users. The underlying product has been used for more than 50 years, with Roundup introduced in 1974 and containing glyphosate as its active ingredient.

In the broader dispute over glyphosate and cancer risk, the evidence provided says the World Health Organization’s International Agency for Research on Cancer classified glyphosate as “probably carcinogenic” in 2015, while the U.S. Environmental Protection Agency determined it is not likely to cause cancer in humans when used as directed. The evidence also indicates about 200,000 Roundup-related claims have been made against Bayer, with many tied to use on residential lawns and gardens. In litigation that has reached juries, outcomes have varied, including a Georgia jury award of $2.1 billion in one case and a Missouri jury verdict in October siding with Bayer in a design-defects, negligence and fraud case.

The settlement was filed in St. Louis Circuit Court and is intended to address most remaining lawsuits, along with additional cases brought in future years by people exposed to Roundup before the settlement was proposed in February.

At a September court hearing about whether the settlement was fair, attorney Gerson Smoger argued the deal could lock in future claimants for decades without the chance at punitive damages and allow the product to remain on the market for additional exposure. Court-appointed counsel Christopher A. Seeger said the final approval order provides “guaranteed compensation” to Roundup cancer victims who have waited more than a decade for justice.

← More stories